Tocilizumab (TCZ) was the first humanized anti-interleukin-6 receptor subunit alpha monoclonal antibody licensed to treat rheumatoid arthritis and systemic juvenile idiopathic arthritis. Here, IL6R is linked to rheumatoid arthritis.